Alkermes plc is a biopharmaceutical company that develops and sells medications targeting neurological and psychiatric conditions, including schizophrenia, bipolar disorder, and substance use disorders, with operations across the United States, Ireland, and other markets. The company markets several approved treatments such as injectable and oral formulations for schizophrenia and bipolar disorder, as well as medications for opioid and alcohol dependence, while maintaining a pipeline of experimental candidates in neurology. Additionally, Alkermes licenses its proprietary drug delivery technology platforms to other pharmaceutical firms and collaborates with entities within the Janssen pharmaceutical group.
1Y: 45.34 (+47.7%) · range 27.20–55.22
entry readiness 21 · NOT READY · exit proximity 0
Value area 39.54–50.83 · 47% of 120d volume overhead · moderate overhead
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +1.70% | +4.01% | mature |
| 40d | -15.62% | +4.01% | mature |